Theranostics in Prostate Cancer

Posted by Phillip J. Koo, MD | Dec 2017

Phillip J. Koo, MD, Banner MD Anderson Cancer Center, Phoenix, Arizona discusses how theranostics will change the way physicians treat prostate cancer by helping select the appropriate patient for therapies and showing which ones respond.

Keywords: prostate cancer, theranostics, nuclear medicine, therapeutics, diagnostic agent

About The Author

Phillip J. Koo, MD

Phillip J. Koo, MD, is the Division Chief of Diagnostic Imaging and Northwest Region Oncology Physician Executive at the Banner MD Anderson Cancer Center in Phoenix, Arizona. Prior to this, he was Chief of Nuclear Medicine and Associate Professor of Radiology at the University of Colorado School of Medicine. Dr. Koo completed his transitional internship at the University of Pennsylvania Medical Center-Presbyterian, his radiology residency at Pennsylvania Hospital of the University of Pennsylvania Health System, and his fellowship at the Harvard Medical School Joint Program in Nuclear Medicine. He is a diplomate of both the American Board of Radiology and the American Board of Nuclear Medicine. Dr. Koo is an active member of multiple societies and has served as the Chair of Nuclear Medicine for the RSNA Scientific Program Committee, Chair of the Quality and Evidence Committee for the Society of Nuclear Medicine and Molecular Imaging (SNMMI), and Chair of the Prostate Cancer Working Group at the SNMMI. Dr. Koo has published on various topics related to radiology and nuclear medicine in multiple journals such as Radiology, Radiographics, the European Journal of Nuclear Medicine and Molecular Imaging, Urology, and the Journal of the American College of Radiology.

Join the GRU Community

- Why Join? -

CARDEN JENNINGS PUBLISHING CO., LTD.

Your GRU

– Account Dashboard
– Your Courses

Recent Updates

PDF Embedder Test Jan 2022
Genetic Testing and Prostate Cancer – Welcome Jan 2022
Current Status of PSMA Diagnostics Aug 2021
Genetic Testing and Prostate Cancer Aug 2021
What’s New in Active Surveillance for Prostate Cancer in 2021 Aug 2021

Exercise & Wellness

Join the GRU Community

Watch, Listen, Learn, and Engage with Experts in the Urology Community.

Theranostics in Prostate Cancer

About The Author

Phillip J. Koo, MD

Join the GRU Community

You have Successfully Subscribed!

CARDEN JENNINGS PUBLISHING CO., LTD.

INFO

Your GRU

– Account Dashboard
– Your Courses

Recent Updates

Exercise & Wellness

Join the GRU Community

You have Successfully Subscribed!

Theranostics in Prostate Cancer

About The Author

Phillip J. Koo, MD

Related Posts

PSMA-11 PET: Atypical Paths to FDA Approval and Academic NDAs

Prostate Brachytherapy

Multimodal Approach to Advanced Prostate Cancer

The Pros and Cons of Evaluating Hematuria

Join the GRU Community

You have Successfully Subscribed!

CARDEN JENNINGS PUBLISHING CO., LTD.

INFO

Your GRU

– Account Dashboard – Your Courses

Recent Updates

Exercise & Wellness

Join the GRU Community

You have Successfully Subscribed!

– Account Dashboard
– Your Courses